Close Menu

As it awaits the publication of in vitro data from its lead cancer program, Australian microRNA drugs startup MirEven has moved into proof-of-concept animal studies to test various oligo chemistries and delivery technologies, a company executive said this week.

MiReven was founded in 2010 to advance the work of co-founder and Western Australian Institute for Medical Research investigator Peter Leedman on the role of miR-7 in regulating epidermal growth factor receptor signaling in cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.